Journey Medical Co. (NASDAQ:DERM - Free Report) - Stock analysts at B. Riley decreased their FY2027 earnings estimates for Journey Medical in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst K. Patel now forecasts that the company will post earnings of $0.31 per share for the year, down from their previous estimate of $0.39. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share.
Several other equities analysts have also recently issued reports on the stock. Alliance Global Partners restated a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Industrial Alliance Securities set a $10.50 price objective on shares of Journey Medical in a research report on Thursday, March 27th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Journey Medical presently has an average rating of "Buy" and an average target price of $9.88.
Get Our Latest Stock Report on Journey Medical
Journey Medical Stock Performance
Shares of NASDAQ:DERM traded up $0.35 during midday trading on Monday, reaching $6.59. 80,509 shares of the company's stock traded hands, compared to its average volume of 85,448. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a one year low of $3.20 and a one year high of $6.89. The company has a market cap of $137.67 million, a price-to-earnings ratio of -7.01 and a beta of 0.90. The stock has a 50 day moving average of $5.29 and a 200 day moving average of $5.20.
Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.30. The business had revenue of $14.30 million for the quarter, compared to analysts' expectations of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.
Insider Buying and Selling at Journey Medical
In other news, CEO Claude Maraoui sold 23,508 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52. Following the completion of the sale, the chief executive officer now owns 2,139,922 shares of the company's stock, valued at $11,106,195.18. This represents a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 105,831 shares of company stock valued at $536,622. 13.16% of the stock is owned by company insiders.
Hedge Funds Weigh In On Journey Medical
Institutional investors and hedge funds have recently made changes to their positions in the business. Tang Capital Management LLC bought a new position in Journey Medical in the fourth quarter worth approximately $6,747,000. PVG Asset Management Corp raised its holdings in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after purchasing an additional 9,005 shares during the period. Geode Capital Management LLC lifted its position in Journey Medical by 13.5% during the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock valued at $613,000 after purchasing an additional 12,882 shares in the last quarter. Citadel Advisors LLC purchased a new position in Journey Medical during the fourth quarter valued at $174,000. Finally, Kovitz Investment Group Partners LLC grew its holdings in Journey Medical by 112.9% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after purchasing an additional 13,105 shares during the period. Hedge funds and other institutional investors own 7.25% of the company's stock.
Journey Medical Company Profile
(
Get Free Report)
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
See Also
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
